Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the hair loss treatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.

A male with early-stage hair loss experienced severe side effects, including sexual dysfunction from finasteride and increased heart rate and fatigue from high-dose minoxidil, leading to discontinuation of both treatments. He is now relying on DHT-blocking shampoos and awaiting new treatments.

The conversation discusses whether Breezula could be considered a cure for hair loss if it stops hair loss without side effects, acknowledging that it's not very effective for regrowing hair. Some believe a combination of hair transplants and topical treatments like Breezula could be effective, while others doubt its efficacy and the practicality of topicals as a cure.

The conversation is about expecting results from Breezula, a hair loss treatment, with no new information released as of April 1st. Some joked it's just onion juice, while another comment suggested a conspiracy to cause baldness.

The conversation is about the availability of Breezula, a hair loss treatment, with speculation it might be released in 2022 or potentially never, as it's more effective than finasteride. No specific treatments were confirmed.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

A user started taking oral minoxidil using Rogaine, despite concerns from others about its safety and proper use. They plan to update on their progress.

User hoodoomoovoo discusses their interest in stem cell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.

User experienced side effects from Minoxidil and is switching to Nanoxidil. They are also using Finasteride and seeking advice on preventing hair loss.

A user shared their experience obtaining a finasteride prescription through Lemonaid, highlighting the ease of the process without needing to provide photos. They chose oral finasteride for preventative hair loss treatment due to a family history of baldness and received a year’s supply at a low cost.

Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.

People are discussing their supplies of hair loss treatments like Minoxidil, finasteride, and dutasteride, with concerns about availability and cost. Many users mention sourcing these medications from India due to lower prices, while others discuss the challenges of obtaining them in Europe.

The conversation discusses increasing the dose of oral minoxidil from 2.5mg to 5mg for better hair density, with concerns about potential side effects like heart rate changes and fluid retention. Users suggest consulting a doctor, considering individual tolerance, and exploring other treatments like dutasteride.

The conversation discusses the use of finasteride for hair loss treatment and addresses misconceptions about its use in hormone replacement therapy. It also touches on the safety and long-term effects of finasteride, with some users expressing skepticism and others defending its safety profile.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

Minoxidil is showing noticeable hair regrowth, but users suggest adding finasteride for better results and longer-lasting effects. Concerns about finasteride's side effects are discussed, but many users report minimal issues.

A user is considering ordering topical finasteride from India due to unavailability in their country and previous side effects from oral finasteride. Users recommend Indian brands like Morr-F and Minscalp F, noting their affordability and effectiveness, while advising to ensure purchases are from reputable sources.

Finasteride and Dutasteride are used to block DHT and treat hair loss, but some people don't respond to these treatments. Alternatives include increasing Dutasteride dosage, adding topical finasteride, or exploring other treatments like RU58841, though results vary.

The conversation discusses whether rosemary oil can be applied directly to the scalp without dilution, with some users suggesting it is already diluted and safe to use. However, many emphasize that treatments like Minoxidil and Finasteride are more effective for hair loss, while rosemary oil is seen as less effective or a placebo.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

Nanoxidil may be more effective than Minoxidil for hair loss due to better follicle penetration, but it lacks widespread recognition and research because it's owned by a small company and classified as a cosmetic. The pharmaceutical system favors Minoxidil due to its established market presence and profitability, leaving Nanoxidil largely unstudied and unknown.

Oral minoxidil is more effective than topical minoxidil for hair regrowth but may cause side effects like heart issues and increased body hair. Combining it with finasteride is common for better results, though side effects vary.

Hair loss changes are typically noticed over months or years, not days, and treatments like finasteride, dutasteride, and minoxidil require time to show effects. People often overreact to daily shedding, but realistic expectations and patience are necessary for hair regrowth treatments.

A 33-year-old attempted hair regrowth after 10 years of baldness using topical finasteride, minoxidil, micro-needling, a laser cap, and later oral dutasteride. They noticed some regrowth, especially vellus hairs, and are considering a hair transplant or other treatments despite side effects.

A user had a successful hair transplant at Diamond Hair Clinic with Dr. Mehmet Demircioglu, noting excellent care and results after 6 months. They now maintain their hair with Dutasteride, oral and topical Minoxidil, and vitamins.

A 24-year-old is using daily dutasteride 0.5 mg for hair loss and considering whether to add minoxidil. Most users suggest continuing with dutasteride alone for now, as it shows promising results and adding minoxidil might cause unnecessary shedding.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.